Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAMP1 | O60894 | 3/20 | 0.34 |
| ▸ | CALCRL | Q16602 | 3/20 | 0.34 |
| ▸ | BACE1 | P56817 | 2/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 3/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13886148 | 0.89 | REN (0.33) | RAMP1CALCRLBACE1RENNAMPT | |
| SCHEMBL8278256 | 0.89 | REN (0.33) | RAMP1CALCRLBACE1RENNAMPT | |
| SCHEMBL1685532 | 0.89 | CYP3A4 (0.34) | RAMP1CALCRLRENNAMPT | |
| SCHEMBL8190835 | 0.85 | REN (0.35) | RAMP1CALCRLBACE1RENNAMPT | |
| SCHEMBL13573774 | 0.85 | REN (0.35) | RAMP1CALCRLBACE1RENNAMPT | |
| SCHEMBL26047191 | 0.85 | REN (0.35) | RAMP1CALCRLBACE1RENNAMPT | |
| SCHEMBL8294160 | 0.85 | DRD2 (0.35) | RAMP1CALCRLRENNAMPTADRB3 | |
| SCHEMBL3799238 | 0.84 | ADRB3 (0.46) | RAMP1CALCRLBACE1RENNAMPT | |
| SCHEMBL3799240 | 0.84 | ADRB3 (0.46) | RAMP1CALCRLBACE1RENNAMPT | |
| SCHEMBL13818335 | 0.84 | ADRB3 (0.46) | RAMP1CALCRLBACE1RENNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | ARRAY BIOPHARMA, INC. | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | EIF2AK2, HAVCR2, HCCS | RAMP1 3904/4885CALCRL 3966/4885BACE1 4146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.